Merging Animal Healthcare Distribution and IT: Launching a New Platform with a $3.5 Billion Big Deal

Cencora, Inc. (NASDAQ: COR) has signed a definitive agreement to merge its animal-health subsidiary, MWI Animal Health, with animal-medical technology firm Covetrus. Under the terms of the transaction, MWI is valued at $3.5 billion (approximately KRW 4.5 trillion), and Cencora will receive $1.25 billion in cash, $800 million of preferred stock, and $1.45 billion of common stock from the combined company, retaining a 34.3% non-controlling common equity stake. The closing is subject to customary conditions, including regulatory approvals. While reaffirming its fiscal 2026 guidance, the company noted that it has not assumed closing the deal within fiscal 2026 in its current outlook.

In its recently reported first quarter of fiscal 2026, Cencora slightly beat consensus earnings-per-share estimates and delivered revenue essentially in line with expectations. The company is also managing its balance sheet, having completed a $3 billion (approximately KRW 3.9 trillion) bond offering in tranches to refinance debt incurred in the OneOncology acquisition.

Cencora is a leading U.S. pharmaceutical wholesaler and distributor, formerly known as AmerisourceBergen until rebranding in 2023. It trades on the New York Stock Exchange under the ticker COR and ranks among the Fortune 500. MWI Animal Health, Cencora’s animal-pharmaceutical distribution arm, will join with Covetrus to create an integrated platform combining animal-health distribution with IT and services for veterinarians—a move expected to further reshape the global animal-health distribution and solutions industry.